INMB Q3 2023 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43,000-56.1% YoY

Gross Profit

$43,000100.0% margin

Operating Income

-$9M-19832.6% margin

Net Income

-$9M-19914.0% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-6.5%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$63M

Total Liabilities

$18M

Stockholders' Equity

$45M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43,000	$98,000	-56.1%
Gross Profit	$43,000	$98,000	-56.1%
Operating Income	-$9M	-$7M	-14.6%
Net Income	-$9M	-$8M	-10.8%